GlobeNewswire by notified

Zoom Whiteboard, the Collaboration Canvas for Hybrid Teams, Now Available

Share

New Solution Enables Real-time and Asynchronous Dispersed Collaboration

SAN JOSE, Calif., April 19, 2022 (GLOBE NEWSWIRE) -- Today, Zoom Video Communications, Inc. announced the general availability of Zoom Whiteboard, a modern digital canvas that provides a unified solution for collaboration and creation within the Zoom platform. Users can interact with the Zoom Whiteboard similar to an in-person experience, creating more visually engaging and efficient collaboration. With the global workforce embracing hybrid work environments across industries, there is an increased need for solutions that seamlessly foster ideation and teamwork among co-located and distributed colleagues. Zoom Whiteboard further broadens the capabilities of the Zoom platform for today’s hybrid workforce, including unified communications, Zoom Developer Platform, Zoom Events, Zoom Contact Center, and Zoom IQ for Sales.

“Collaboration tools are in high demand, and Zoom Whiteboard is sure to be a staple in the modern workforce,” said Dan Root, Senior Analyst of Visual Collaboration, Wainhouse Research. “Zoom brings over a decade’s worth of experience in exceptional video communications to this new solution, which businesses need to keep information flowing in a secure and easily-managed fashion.”

“Not only are we supporting customers as they adapt to this new phase of work, but we’re anticipating what comes next, and building platform solutions, like Zoom Whiteboard, to address it,” said Oded Gal, Chief Product Officer of Zoom. “Zoom Whiteboard is arming teams with the power of continuous communication in an easy-to-use solution that provides a virtual space to collaborate before, during, and after a meeting.”

Whiteboard Anytime, From Anywhere
Hybrid work presents challenges for working collaboratively as remote workers can’t see a physical whiteboard in the office and risk being left out. It can also be challenging to transport ideas and information across a broad audience.

Zoom Whiteboard is a visual collaboration tool designed to facilitate asynchronous and real-time collaboration, serving as a virtual space for teams to capture ideas and work together with freedom and flexibility. A web-based solution, users can effortlessly collaborate across a variety of devices – web browser, tablet, desktop, or Zoom Rooms for Touch. Tightly integrated with Zoom Meetings and Zoom Rooms for Touch devices like the DTEN D7 and Neat Board, with support for Zoom Chat coming soon, Zoom Whiteboard extends productivity well beyond the boundaries of a single meeting.

Complement your Zoom Rooms with a dedicated Companion Whiteboard, like the new DTEN ONboard, the first purpose-built interactive touch display for advanced whiteboarding coming soon.

Features Designed for Collaboration
Zoom Whiteboard comes with a host of easy-to-use features including:

  • Dashboard and easy sharing: Create new, manage existing, and share access to whiteboards. Zoom Whiteboard can be shared internally or externally with anyone that has a Zoom account, with the option to export and save.
  • Notes and comments: Use sticky notes to highlight important ideas.
  • Shapes and Connectors: Shapes are easily created, and connectors can be used to instantly attach those shapes.
  • Extendable Canvas: Create up to 12 pages with seamless navigation; users can easily add images.

To learn more about Zoom Whiteboard, please visit the Whiteboard page and read our blog.

About Zoom
Zoom is for you. Zoom is a space where you can connect to others, share ideas, make plans, and build toward a future limited only by your imagination. Our frictionless communications platform is the only one that started with video as its foundation, and we have set the standard for innovation ever since. That is why we are an intuitive, scalable, and secure choice for large enterprises, small businesses, and individuals alike. Founded in 2011, Zoom is publicly traded (NASDAQ:ZM) and headquartered in San Jose, California. Visit zoom.com and follow @zoom.

Zoom Public Relations
Farshad Hashmatulla
Product PR Manager
press@zoom.us

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

ERYTECH to Present at the H.C. Wainwright Global Investment Conference17.5.2022 22:05:00 CEST | Press release

ERYTECHtoPresent at the H.C. WainwrightGlobal Investment Conference Cambridge, MA (U.S.) and Lyon (France), May 17, 2022 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that its Chief Executive Officer, Gil Beyen, will present at the H.C. Wainwright Global Investment Conference. The conference will be held in a hybrid format from May 23-26, 2022, in Miami, USA. The corporate presentation will be held in person on Wednesday, May 25 at 10:30am ET and will be available on-line on the conference website afterwards. Mr. Beyen will be available for one-to-one meetings with investors on May 24, 25 and 26. If you would like to arrange a one-on-one meeting or register, please contact your conference representative. For more information on the H.C. Wainwright 23rd Global Investment Conference, please visit the H.C. Wainwright Conference websi

EVS COMMUNICATES THE RESULTS OF THE ORDINARY GENERAL MEETING17.5.2022 21:59:34 CEST | Press release

Publication on May17, 2022, after market closure Regulated information EVS Broadcast Equipment S.A.: Euronext Brussels (EVS.BR), Bloomberg (EVS BB), Reuters (EVSB.BR) EVSCOMMUNICATES THERESULTSOFTHEORDINARYGENERAL MEETING EVS Broadcast Equipment SA, leading provider of live video production systems, held its Ordinary General Meeting on May 17, 2022. In total 73 shareholders representing 2,799,870 shares, or 19.5% of the company shares, attended by proxy the Ordinary General Meeting held physically at the company's registered office but for which the company had recommended its shareholders to attend by videoconference given the still sensitive health situation. All the resolutions have been approved, i.e.: - The remuneration report, the updated remuneration policy, the discharge of the Directors and the Auditor; - The 2021 annual accounts and the allocation of profits, including a total gross dividend of EUR 1.50 for fiscal year 2021 (such dividend is made up, on the one hand, of the i

SeaLegacy Celebrates the Inaugural Year of The Good Ocean17.5.2022 21:49:59 CEST | Press release

A unified, passionate group of businesses investing in SeaLegacy’s mission to protect the world’s oceans British Columbia, Canada, May 17, 2022 (GLOBE NEWSWIRE) -- When eight companies mostly unknown to one another came together for the first time in May of 2021, they were bound only by a commitment to protect our oceans and planet. Today, these founding members of The Good Ocean are actively supporting SeaLegacy’s commitment to ocean protection. "One of the questions I get asked the most is, 'What can I do?'" says SeaLegacy Co-Founder and President Cristina Mittermeier. "This question comes from individuals, and it also comes from businesses. Increasingly, consumers are demanding the products and services they support with their purchasing power be aligned with their desire to be accountable for their impact on earth. Members of The Good Ocean are addressing that demand and stepping into the crucial role businesses play in conservation work. Together, we are taking steps towards syste

Karolinska Development’s portfolio company Aprea Therapeutics acquires Atrin Pharmaceuticals17.5.2022 16:55:38 CEST | Press release

STOCKHOLM, SWEDEN, May 17 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company Aprea Therapeutics has completed the acquisition of the privately-held US-based biotechnology company Atrin Pharmaceuticals Inc. Aprea Therapeutics will now prioritize the development of Atrin Pharmaceuticals’ drug candidates, which are being developed to fight cancer by affecting the proteins involved in the ability of tumors to repair damage to their DNA. With the acquisition of Atrin Pharmaceuticals’ portfolio of candidate drugs, Aprea Therapeutics intends to shift its primary focus to the development of ATRN-119, a drug candidate that inhibits an important signaling pathway in DNA damage repair. ATRN-119 will soon be evaluated in clinical phase 1/2a studies in the treatment of malignant solid tumors, both as monotherapy and in combination with standard treatment. In parallel with the development of ATRN-119, separate programs are run with a second-generation ATR i

Karolinska Developments portföljbolag Aprea Therapeutics förvärvar Atrin Pharmaceuticals17.5.2022 16:55:38 CEST | Pressemelding

STOCKHOLM, SVERIGE 17 maj 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget Aprea Therapeutics har förvärvat det privatägda amerikanska bioteknikbolaget Atrin Pharmaceuticals Inc. Aprea Therapeutics kommer nu att prioritera utvecklingen av Atrin Pharmaceuticals läkemedelskandidater, vilka utvecklas för att bekämpa cancersjukdomar genom att påverka de proteiner som är involverade i tumörers förmåga att reparera skador i sitt DNA. Efter förvärvet av Atrin Pharmaceuticals läkemedelsprojekt flyttar Aprea Therapeutics sitt primära fokus till utvecklingen av ATRN-119, en läkemedelskandidat som hämmar en viktig signaleringsväg vid reparation av DNA-skador. ATRN-119 kommer inom kort att börja studeras i kliniska fas 1/2a-studier vid behandling av maligna solida tumörer, både som monoterapi och i kombination med standardbehandling. Parallellt med utvecklingen av ATRN-119 bedrivs separata program med en andra generationens ATR-hämmare, ATRN-354, med poten